| Primary |
| Drug Use For Unknown Indication |
45.3% |
| Reversible Ischaemic Neurological Deficit |
9.3% |
| Anaesthesia |
4.7% |
| Foetal Exposure During Pregnancy |
4.7% |
| Nasopharyngitis |
4.0% |
| Pupil Dilation Procedure |
4.0% |
| Hypotension |
3.3% |
| Induction Of Anaesthesia |
3.3% |
| Product Used For Unknown Indication |
3.3% |
| Influenza |
2.7% |
| Contraception |
2.0% |
| Influenza Like Illness |
2.0% |
| Nasal Congestion |
2.0% |
| Blood Pressure Management |
1.3% |
| Bradycardia |
1.3% |
| Coronary Artery Disease |
1.3% |
| Dyspnoea |
1.3% |
| General Anaesthesia |
1.3% |
| Intraocular Pressure Increased |
1.3% |
| Multiple Allergies |
1.3% |
|
| Drug Dependence |
30.8% |
| Lung Infiltration |
17.3% |
| Blood Lactic Acid Increased |
5.8% |
| Dependence |
5.8% |
| Hyperhidrosis |
3.8% |
| Hypotension |
3.8% |
| Maternal Exposure During Pregnancy |
3.8% |
| Pupillary Block |
3.8% |
| Subarachnoid Haemorrhage |
3.8% |
| Anaesthetic Complication |
1.9% |
| Atrioventricular Block Second Degree |
1.9% |
| Blindness |
1.9% |
| Blood Creatine Phosphokinase Mb Increased |
1.9% |
| Cardio-respiratory Arrest |
1.9% |
| Dyspnoea |
1.9% |
| Electrocardiogram T Wave Inversion |
1.9% |
| Erythema |
1.9% |
| Haemorrhage |
1.9% |
| Hypersensitivity |
1.9% |
| Hypertensive Crisis |
1.9% |
|
| Secondary |
| Postoperative Care |
33.0% |
| Preoperative Care |
16.5% |
| Anaesthesia |
11.3% |
| Nasopharyngitis |
6.5% |
| Hypotension |
4.1% |
| Influenza Like Illness |
4.1% |
| Cataract Operation |
3.9% |
| Product Used For Unknown Indication |
3.5% |
| Prophylaxis |
2.8% |
| Influenza |
2.0% |
| Vascular Operation |
2.0% |
| Foetal Exposure During Pregnancy |
1.7% |
| Contraception |
1.5% |
| Drug Use For Unknown Indication |
1.3% |
| Anaesthesia Procedure |
1.1% |
| Drug Exposure During Pregnancy |
1.1% |
| Nasal Congestion |
1.1% |
| Ophthalmological Examination |
1.1% |
| Blood Pressure Management |
0.9% |
| Cycloplegia |
0.7% |
|
| Toxic Anterior Segment Syndrome |
35.1% |
| Drug Exposure During Pregnancy |
13.5% |
| Inflammation |
10.8% |
| Drug Hypersensitivity |
5.4% |
| Placental Disorder |
5.4% |
| Subarachnoid Haemorrhage |
4.1% |
| Atrioventricular Block Second Degree |
2.7% |
| Bronchopneumonia |
2.7% |
| Confusional State |
2.7% |
| Corneal Abrasion |
2.7% |
| Maternal Exposure During Pregnancy |
2.7% |
| C-reactive Protein Increased |
1.4% |
| Condition Aggravated |
1.4% |
| Delayed Recovery From Anaesthesia |
1.4% |
| Drug Effect Prolonged |
1.4% |
| Drug Eruption |
1.4% |
| Eye Pain |
1.4% |
| Foetal Exposure During Pregnancy |
1.4% |
| Foetal Heart Rate Disorder |
1.4% |
| Haemorrhage |
1.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
48.7% |
| Product Used For Unknown Indication |
25.2% |
| Anaesthesia Procedure |
3.1% |
| General Anaesthesia |
3.0% |
| Epidural Anaesthesia |
2.9% |
| Anaesthesia |
2.4% |
| Pain |
2.4% |
| Retinal Detachment |
2.1% |
| Immunosuppression |
1.1% |
| Hypotension |
1.0% |
| Maintenance Of Anaesthesia |
1.0% |
| Rhabdomyosarcoma |
1.0% |
| Induction Of Anaesthesia |
1.0% |
| Gastrooesophageal Reflux Disease |
0.9% |
| Anaesthetic Complication Vascular |
0.8% |
| Antibiotic Therapy |
0.8% |
| Hypertension |
0.8% |
| Muscle Relaxant Therapy |
0.7% |
| Premedication |
0.7% |
| Prophylaxis |
0.7% |
|
| Vomiting |
10.7% |
| Rhabdomyolysis |
7.1% |
| Tachycardia |
7.1% |
| Toxic Anterior Segment Syndrome |
7.1% |
| Altered State Of Consciousness |
5.4% |
| Rash |
5.4% |
| Renal Failure Acute |
5.4% |
| Sputum Retention |
5.4% |
| Thrombocytopenia |
5.4% |
| Unresponsive To Stimuli |
5.4% |
| Cardiac Arrest |
3.6% |
| Cellulitis Orbital |
3.6% |
| Chest Pain |
3.6% |
| Floppy Iris Syndrome |
3.6% |
| Pain |
3.6% |
| Presyncope |
3.6% |
| Procedural Complication |
3.6% |
| Respiratory Failure |
3.6% |
| Sensory Loss |
3.6% |
| Subcutaneous Emphysema |
3.6% |
|
| Interacting |
| Induction Of Anaesthesia |
53.3% |
| Parkinson's Disease |
26.7% |
| Prophylaxis |
6.7% |
| Retinoblastoma |
6.7% |
| Thrombosis Prophylaxis |
6.7% |
|
| Anaesthetic Complication |
33.3% |
| Inhibitory Drug Interaction |
33.3% |
| Off Label Use |
33.3% |
|
